Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Add as a preferred source on Google
NEW YORK, Feb. 27, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of DaVita Inc. securities (NYSE:DVA) from August 5, 2015 through October 21, 2016, inclusive (the “Class Period”). The lawsuit seeks to recover damages for DaVita investors under the federal securities laws.
To join the DaVita class action, go to http://rosenlegal.com/cases-1026.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into unnecessary insurance plans in order to maximize profits; (2) DaVita was using American Kidney Fund as a vehicle to facilitate these improper practices; (3) as such, DaVita’s revenues and profits were illegally obtained; (4) in turn, DaVita lacked effective internal controls over financial reporting; and (5) as a result, Defendants’ statements about DaVita’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1026.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
